AGS-003 Plus Standard Treatment in Advanced RCC (ADAPT)

• Research type

  Research Study

• Full title

  An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

• IRAS ID

  127017

• Contact name

  Tim Eisen

• Contact email

  TGQE2@cam.ac.uk

• Sponsor organisation

  Argos Therapeutics, Inc.

• Eudract number

  2012-000871-17

• Clinicaltrials.gov Identifier

  NCT01582672

• REC name

  London - West London & GTAC Research Ethics Committee

• REC reference

  13/LO/0733

• Date of REC Opinion

  25 Sep 2013

• REC opinion

  Further Information Favourable Opinion